AbbVie Inc. (ABBV) News

AbbVie Inc. (ABBV): $139.22

0.51 (+0.37%)

POWR Rating

Component Grades













Filter ABBV News Items

ABBV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ABBV News Highlights

  • For ABBV, its 30 day story count is now at 20.
  • Over the past 11 days, the trend for ABBV's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • SKIN, BODY and JNJ are the most mentioned tickers in articles about ABBV.

Latest ABBV News From Around the Web

Below are the latest news stories about ABBVIE INC that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

3 Great Dividend Stocks to Buy in September

Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie boasts practically all the characteristics of an outstanding dividend stock, including a stable business with increasing revenue and earnings, solid growth avenues, a juicy yield, a conservative payout ratio, and of course, an impressive history of dividend hikes.

Yahoo | September 3, 2022

5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons Why

There's no better time to build a strong watchlist of great companies than during a serious market correction. In 2022, the NYSE's composite index continues to outperform its Nasdaq sibling. Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak.

Yahoo | September 2, 2022

3 Dividend Stocks to Buy in September for Passive Income Generation

Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. Here's how they could provide ever-increasing dividend payments to your brokerage account. Shares of Abbott Laboratories (NYSE: ABT) have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests.

Yahoo | September 1, 2022

Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study

The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic syndrome. Shares down.

Yahoo | August 31, 2022

SkinMedica® Launches Firm & Tone Lotion for Body

Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of SkinMedica® Firm & Tone Lotion for Body, the first product from the professional-grade skincare line formulated to prevent and address visible signs of body skin aging for a toned look.1 It is clinically proven to diminish the look of crepey skin, address uneven skin texture, improve the appearance of body skin firmness and tone, and improve the look of sagging skin.1

Yahoo | August 31, 2022

10 Best Stocks That Pay Monthly Dividends

In this article, we discuss 10 best stocks that pay monthly dividends. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Best Stocks That Pay Monthly Dividends. In July 2022, the Consumer Price Index rose 8.5% from a year ago, marking a little […]

Yahoo | August 30, 2022

Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report

Allergan Aesthetics, an AbbVie company, and a global leader in medical aesthetics treatments, today announces the U.S. publication of 'The Future of Aesthetics' global trends report, developed to understand what is shaping the aesthetics industry of tomorrow.

Yahoo | August 30, 2022

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Recently, users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Yahoo | August 29, 2022

AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress

AbbVie (NYSE: ABBV) today announced it will present 23 abstracts at the 31st European Academy of Dermatology and Venereology (EADV) Congress, including a late-breaking oral presentation on long-term efficacy and safety data of SKYRIZI® (risankizumab) in psoriatic arthritis and real-world data from MEASURE-AD to assess the multidimensional burden of atopic dermatitis. This research demonstrates AbbVie's commitment to deepening the understanding of immune-mediated skin diseases by investing in stu

Yahoo | August 29, 2022

The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer

Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.

Yahoo | August 29, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.549 seconds.